Composition, form of production and packaging
Vaginal and rectal suppositories 1 supp.
interferon alfa-2b 500,000 IU
sodium hyaluronate 12 mg
Excipients: confectionary fat, paraffin, emulsifier T-2.
10 pieces. - paper (1) wax - cardboard packs.
5 pieces. - blisters (2) - packs of cardboard.
10 pieces. - packings of cellular contour (1) - packs cardboard.
INSTRUCTION FOR THE SPECIALIST.
Description of the drug approved by the manufacturer for the printed edition of 2010.
PHARMACHOLOGIC EFFECT
Interferon alfa-2b human recombinant is a protein obtained through recombinant DNA. The polypeptide structure of the molecule, biological activity and pharmacological properties are identical to leukocyte interferon alpha-2b.
Interferon alfa-2b human recombinant inhibits the intracellular stages of the development of the herpes simplex virus type I and II, chlamydia, gardnerella, mycoplasma and ureaplasma, has antiviral, immunomodulatory and antibacterial effects.
PHARMACOKINETICS
When the drug is injected interferon alpha-2b human recombinant is absorbed through the mucosa, enters the surrounding tissues, into the lymphatic system, providing a systemic immunomodulatory effect. Due to partial fixation on the cells of the mucous membrane also has a local effect. When intravaginal application due to high concentration in the focus of infection has a pronounced local antiviral and antibacterial effect. The maximum concentration of interferon in the serum is reached 5 hours after the administration of the drug. Due to the pronounced hydrophilicity of sodium hyaluronate forms a dispersed matrix, promotes the enhancement of the activity and proliferation of cellular elements, accelerates the regeneration of tissues, stimulates angiogenesis. As the main structural element of the human connective tissue, sodium hyaluronate provides a uniform, prolonged penetration of interferon into the bloodstream.
Reduction of the level of serum interferon 12 hours after the administration of the drug necessitates its repeated administration.
INDICATIONS
- acute and chronic recurrent herpetic infection; in t.ch. sexual and generalized forms;
- complex therapy of genital sphere diseases: chlamydia, gardnerellez, mycoplasmosis and ureaplasmosis.
DOSING MODE
Before use, the wax paper is removed from the suppository or the cell packaging is cut.
For herpes infection : 1 suppository rectally or vaginally 2 times a day, daily for 10 days.
With chlamydia, gardnerellez, mycoplasmosis, ureaplasmosis : 1 suppository 2 times a day vaginally daily for 20-30 days.
SIDE EFFECT
The drug is well tolerated and does not cause significant side effects. At a daily dose of interferon alpha-2b above 10,000,000 IU, there may be phenomena such as chills, fatigue, loss of appetite, sweating. In these cases it is advisable to consult a doctor to reduce the dose of the drug.
CONTRAINDICATIONS
- increased individual sensitivity to the components of the drug.
PREGNANCY AND LACTATION
The use of the drug during pregnancy and lactation has not been studied.
SPECIAL INSTRUCTIONS
Giaferon does not affect the performance of activities requiring special attention and quick reactions (management of vehicles, machinery, etc.).
The drug is not suitable for use:
- the integrity of the package, which is broken;
- without marking;
- with altered physical properties (discoloration, odor of rancid fat);
- expired.
OVERDOSE
Cases of an overdose of the drug Giaferon are not registered.
DRUG INTERACTION
The drug Giaferon is effective as a component of complex therapy. In combination with antibacterial and antiviral drugs it is possible to achieve a high therapeutic effect.
TERMS OF RELEASE FROM PHARMACY
Without recipe.
TERMS AND CONDITIONS OF STORAGE
In accordance with JV 3.3.2.1248-03. At a temperature of 2 to 8 В° C. Shelf life - 1 year.
